Aarti Drugs Limited reported earnings results for the second quarter and six months ended September 30, 2025. For the second quarter, the company reported sales was INR 6,527.9 million compared to INR 5,983.3 million a year ago. Revenue was INR 6,528.8 million compared to INR 5,998.1 million a year ago. Net income was INR 452.8 million compared to INR 350.1 million a year ago. Basic earnings per share from continuing operations was INR 4.58 compared to INR 3.33 a year ago. Diluted earnings per share from continuing operations was INR 4.58 compared to INR 3.33 a year ago.
For the six months, sales was INR 12,433 million compared to INR 11,536.7 million a year ago. Revenue was INR 12,437 million compared to INR 11,562.6 million a year ago. Net income was INR 991.9 million compared to INR 682.5 million a year ago. Basic earnings per share from continuing operations was INR 9.91 compared to INR 6.28 a year ago. Diluted earnings per share from continuing operations was INR 9.91 compared to INR 6.28 a year ago.
Aarti Drugs Limited is an India-based company, which is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates in the pharmaceuticals segment. Its geographical segments include Out of India and India. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals include benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
